Showing results (21-30 of 88) with videos related to
Sort By:
Pageof 9
Leukemia & Lymphoma|October 25, 2008
Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani, Farrukh T Awan, Patrick Elder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2007
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteriaKristie A Blum, Donn Young, Sarah Broering, et al.Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphomaJonathon B Cohen, Amy S Ruppert, Nyla A Heerema, et al.Clinical Lymphoma, Myeloma & Leukemia|June 18, 2017
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin LymphomaJoseph J Maly, Beth A Christian, Xiaohua Zhu, et al.Clinical Lymphoma, Myeloma & Leukemia|August 18, 2020
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell LymphomaAndrew D Zelenetz, Leslie L Popplewell, Ariela Noy, et al.British Journal of Haematology|July 17, 2009
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemiaTait D Shanafelt, John C Byrd, Betsy LaPLant, et al.British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.Cancer|September 20, 2013
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphomaRobert A Baiocchi, Lapo Alinari, Mark E Lustberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicitySyed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.Leukemia & Lymphoma|April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.Pageof 9